Trial Profile
A Phase IV, Randomized, Open-label Study to Evaluate One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens (Zagreb 2-1-1 and Essen 1-1-1-1-1) in Chinese Children
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Rabies vaccine (Primary)
- Indications Rabies
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 22 Feb 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 27 Jul 2017 Planned initiation date changed from 30 Jun 2017 to 15 Feb 2018.
- 22 Jun 2017 New trial record